CBD Oil Benefits: Cancer, Pain, Anxiety, and More

The relationship in between infection and standard prescription antibiotics

Could CBD work in the battle versus resistant bacterial stress? The results from the University of Queensland in Australia suggest that it is possible. But prior to analyzing the study in depth, it is useful to understand the advancement of the relationship in between germs and prescription antibiotics.

Given that the innovative discovery of penicillin by Alexander Fleming in 1928, prescription antibiotics have been a necessary tool in the battle versus germs and infections. And although we still utilize the same proven methods today, germs have evolved. When exposed to prescription antibiotics, specific germs, fungi and parasites have the ability to adjust and cancel the efficiency of the drug by developing resistance.

It’s worth mentioning that antimicrobial resistance was most likely to take place anyway, as the hereditary code for germs changes with time. However, it is thought that the overuse of prescription antibiotics is a crucial factor that speeds up the development of resistant stress.

According to the World Health Organization, antimicrobial resistance “is a significantly severe threat to global public health that needs action in all sectors of federal government and in society.” This has led scientists to think outside package by trying to identify compounds that could be useful in the battle versus damaging germs. One of these compounds is cannabidiol (CBD), a cannabinoid discovered in Cannabis sativa.

Researchers are looking for new methods to assault infections and resistant germs.

Dr. Mark Blaskovich, Principal Investigator and Program Coordinator for the Community for Open Antimicrobial Drug Discovery and Senior Research Officer at the Institute for Molecular Bioscience at the University of Queensland, concluded that CBD is effective versus Gram-positive germs. Stress of Gram-positive germs include Staphylococcus aureus (typical in skin infections) and Streptococcus pneumoniae (typical in bacterial pneumonia).

Dr. Blaskovich presented his findings at an annual meeting of the American Society for Microbiology. In vitro samples of both types of gram-positive germs were treated with synthetic CBD. The outcomes led Dr. Blaskovich to the conclusion that CBD works at levels comparable to those of prescription antibiotics vancomycin and daptomycin. He also discovered that CBD appeared to work against gram-positive stress of resistant germs, which lots of standard prescription antibiotics are starting to fail.

” In particular, the activity was selected versus the resistant stress of Staphylococcus aureus (MRSA, VISA, SARV), Streptococcus pneumoniae (MDR), and Enterococcus faecalis (ERV). Cannabidiol was bactericidal, had a low tendency to induce resistance and was active versus MRSA biofilms. “

The group also carried out another study using topical CBD to treat a skin infection in mice. Once again, although the outcomes were positive, CBD did not appear to remove the infection, but merely to minimize the variety of bacterial cells.

Could CBD end up being an antibiotic?

While it is simple to hail this work as a substantial breakthrough in the antibacterial capabilities of CBD, it is prematurely to quit on penicillin.

Although it is thought that the efficiency of CBD might come from the way it attacks the biofilm surrounding bacterial cells, the authors are still not sure of the mechanism of action of CBD. They also did not think twice to explain the shortcomings of the study. Dr. Blaskovich pointed out that considering that the outcomes remain in the preliminary phases, it is far prematurely for people to begin treating their CBD stream infections themselves.

The study was also carried out in vitro (outside the human body), and there is a danger that the outcomes of clinical trials will not be the same. A number of compounds have shown antibacterial effectiveness in petri meals, but then stopped working at this important phase. It must also be pointed out that the two research studies were carried out in cooperation with Botanix Pharmaceuticals Ltd, a pharmaceutical company specializing in topical CBD products.

However, this research study could be a crucial advance for CBD and the battle versus antimicrobial resistance. CBD topia continues to have an excellent safety profile and is not considered harmful even in big amounts. Luckily, Dr. Blaskovich and his group strategy to continue their research study.

Scroll to top